Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Understanding The Gravity Of What Ur Dealing With @ AGN

AIF - Medical Device Development Program - Page 20-21

webfiles.thecse.com/sedar_filings/00037722/1904160953176150.pdf

While the study of breath has been the focus of scientific research for decades, the last 17 years has seen the greatest number of clinical trials. There have been over 448 breath analysis clinical trials for respiratory and non-respiratory diseases. It is noteworthy to state that only one breath test (H.pylori) has been approved by the FDA. One of the possible causes is that an accurate POC device has not yet been developed that would allow researchers the improved sensitivity and specificity required to research and develop to an effective screening or diagnostic breath based test.

According to the report in 2016 by Zion Market Research, the global demand for breath analyzer market was valued at US$500 million in 2015 and is expected to reach US$1.6 billion in 2021, growing at a compound annual growth rate of 25% between 2016 and 2021. This report includes all applications of breathalyzer devices including medical. The report further states that growing demand from healthcare industry for disease identification is one of the major driving factors for growth of market. Unhygienic conditions for use and lower accuracy of the devices are expected to hamper the growth of breath analyzer market over the years. However, ongoing research and development in the breath analyzer devices market is expected to open up new growth opportunities in coming years.

Breath Analyzer - 1.6 Billion Dollar Market - Timeline ????

NASH|CKD|IBD - 53.6 Billion Dollar Market - Timeline Q3 2020 & Q1 2021

I C The Upside of Phase IIa Clinical Trials.

YO RJ!

Let’s Get Some Zero Gravity Practice In B4 Takeoff >`>`>`

GL2ALL

/////AMG